Does BPH increase the risk of prostate cancer?

No. BPH and prostate cancer are separate conditions that happen to become more common in the same age group, but BPH does not cause or predispose to malignancy. They can coexist, and both can elevate PSA levels, which is why men with BPH should still follow age-appropriate prostate cancer screening — typically starting at age 50, or 40 with a family history.

Can BPH be reversed naturally?

Mild symptoms can improve meaningfully with lifestyle changes — reducing caffeine and alcohol, adjusting fluid timing, losing excess weight, and increasing physical activity. However, once the prostate has significantly enlarged, lifestyle measures are unlikely to reverse the structural changes. Medications can slow further growth and reduce symptoms, but most men with moderate-to-severe BPH (IPSS score above 8) will need ongoing medical management rather than lifestyle changes alone.

Does testosterone therapy make BPH worse?

This is a reasonable concern, since DHT derived from testosterone is the primary driver of prostate cell growth. Current evidence does not show that testosterone replacement therapy at physiological doses — restoring levels to the normal range — significantly worsens BPH or meaningfully raises prostate cancer risk in men who are properly screened beforehand. That said, long-term randomized trial data are limited. Standard practice includes monitoring PSA and urinary symptoms at regular intervals during TRT, typically at 3 months and then annually.

What is the difference between BPH and prostatitis?

BPH is a non-inflammatory, hormone-driven overgrowth of prostate tissue that primarily causes obstructive urinary symptoms. Prostatitis is inflammation of the prostate — either from bacterial infection or non-infectious mechanisms — and typically presents with pelvic or perineal pain, burning on urination, and sometimes fever or flu-like symptoms. The two conditions can coexist, and a clinician can distinguish between them through history, examination, urinalysis, and urine culture.

Are BPH medications covered by provincial drug plans in Canada?

Most first-line BPH medications are listed on provincial formularies, but coverage details vary. Tamsulosin (an alpha-blocker) and finasteride (a 5-alpha reductase inhibitor) are included on the Ontario Drug Benefit formulary and most other provincial plans, generally with a standard co-pay for eligible beneficiaries. Dutasteride coverage is more variable. Men with private insurance or those enrolled in provincial benefit programs should confirm specific coverage with their pharmacist, as listing status and co-pay tiers are updated periodically.

Benign prostatic hyperplasia — Glossary

What it is

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that affects roughly 50% of men in their 50s and up to 90% of men in their 80s, making it one of the most prevalent age-related conditions in male health. Also called an enlarged prostate, BPH is the clinical term for non-malignant overgrowth of prostate tissue that compresses the urethra and restricts urine flow.

The prostate is a walnut-sized gland sitting just below the bladder and encircling the urethra — the tube that carries urine out of the body. As prostate tissue accumulates, it narrows the urethral channel, producing the cluster of lower urinary tract symptoms (LUTS) that most men associate with the condition. BPH is not cancer, does not transform into cancer, and does not independently raise prostate cancer risk — though both conditions become more common with age and can coexist.

In Canada, BPH is a leading reason men over 50 visit a family physician or urologist. PSA testing and digital rectal examination (DRE) are available through provincial health plans, and first-line medications — including tamsulosin and finasteride — appear on most provincial formularies, though coverage details vary by province.

Causes and mechanism

BPH is driven by age-related hormonal shifts within prostate tissue, not by systemic testosterone levels alone. The enzyme 5-alpha reductase converts testosterone into dihydrotestosterone (DHT) inside the prostate. DHT is the primary stimulus for prostate cell proliferation, and prostate cells become progressively more sensitive to it with age — even as circulating testosterone declines. Critically, BPH does not occur in men castrated before puberty or in men with conditions that block androgen production, confirming the androgen-dependence of the process.

A second hormonal factor is the shifting estrogen-to-testosterone ratio in aging men. Relatively higher estrogen levels appear to sensitize prostate tissue to DHT's growth-promoting effects, though the precise mechanism is still being characterized.

Key risk factors:

Risk factor	Evidence strength
Age (rare before 40; near-universal by 80s)	Strong
First-degree family history of BPH	Moderate
Obesity and metabolic syndrome	Moderate
Physical inactivity	Moderate
Type 2 diabetes	Emerging

Symptoms and diagnosis

BPH symptoms arise from two sources: mechanical compression of the urethra by the enlarged gland, and secondary changes in bladder muscle function caused by chronic outflow resistance. Prostate size does not reliably predict symptom severity — some men with modestly enlarged glands have significant symptoms, while others with substantially enlarged prostates have few complaints.

Common symptoms include a weak or intermittent urine stream, hesitancy at the start of urination, post-void dribbling, frequent urination (especially nocturia — waking at night to void), urgency, and a persistent sense of incomplete bladder emptying. Acute urinary retention — a sudden, complete inability to void — is the most serious acute complication and requires emergency catheterization.

Diagnosis typically involves:

International Prostate Symptom Score (IPSS) — a validated questionnaire grading symptom severity from mild (0–7) to moderate (8–19) to severe (20–35).
Digital rectal examination (DRE) — estimates prostate size and screens for nodules that might suggest malignancy.
PSA blood test — primarily used to help exclude prostate cancer; PSA can be mildly elevated in BPH.
Urinalysis — rules out infection or haematuria from other causes.
Uroflowmetry and post-void residual ultrasound — objectively measures flow rate and residual urine volume.

In Canada, LifeLabs and Dynacare both process PSA and urinalysis panels; requisitions are typically issued by a family physician before urology referral.

Treatment options

Treatment is matched to symptom severity and patient preference. Men with mild symptoms (IPSS ≤7) and no complications are reasonable candidates for watchful waiting alongside lifestyle adjustments.

Lifestyle modifications — reducing evening fluid intake, limiting caffeine and alcohol, and practising timed voiding — can meaningfully reduce symptom burden in mild to moderate cases without medication.

Alpha-blockers (tamsulosin, alfuzosin, doxazosin) relax smooth muscle in the prostate and bladder neck, improving flow within days to weeks. They are the most commonly prescribed first-line agents and are listed on most provincial drug benefit formularies.

5-alpha reductase inhibitors (finasteride, dutasteride) block DHT production, gradually shrinking the prostate over 6–12 months. They are most effective in men with significantly enlarged glands (prostate volume >40 mL) and reduce the long-term risk of acute urinary retention and the need for surgery.

Combination therapy — an alpha-blocker plus a 5-alpha reductase inhibitor — outperforms either drug alone for men with large prostates and moderate-to-severe symptoms, as demonstrated in the MTOPS and CombAT trials.

Minimally invasive procedures include transurethral resection of the prostate (TURP, the surgical benchmark), UroLift (prostatic urethral lift), and various laser therapies. These are considered when medications fail or when complications such as recurrent retention, bladder stones, or upper-tract damage are present.

Open or robotic prostatectomy is reserved for very large glands or refractory cases where endoscopic approaches are not feasible.

When to see a clinician in Canada

See a family physician or urologist if urinary symptoms — weak stream, hesitancy, nocturia, urgency — are affecting sleep or daily function. Acute urinary retention (complete inability to void) is a medical emergency: go to an emergency department or call 911. Blood in the urine always warrants investigation to exclude malignancy or stones, even if BPH is already diagnosed.

Canadian guidelines generally recommend that men discuss prostate health starting at age 50, or at 40 if there is a first-degree family history of prostate disease. Telehealth platforms operating in Canada — including Maple, Felix, and Cleo — can facilitate initial symptom assessment and PSA requisitions, with urology referral arranged through the provincial system when indicated.

Limitations and open questions

Research is still emerging on the precise role of estrogen in BPH pathogenesis; clinical trials targeting estrogen receptors in the prostate have not yet produced practice-changing results. The long-term cardiovascular effects of alpha-blockers in older men with comorbid hypertension remain an area of active study. Health Canada has not issued specific guidance on BPH management distinct from general urology practice, and provincial formulary coverage for newer minimally invasive procedures such as UroLift varies considerably across Canada. The relationship between testosterone replacement therapy (TRT) and BPH progression is also not fully settled — current evidence at physiological replacement doses is generally reassuring, but long-term data from large randomized trials are limited. Men considering TRT who have existing BPH should discuss monitoring protocols with their prescribing clinician.

Benign prostatic hyperplasia